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The soluble 155 kDa glycoprotein factor H (FH) protects host
tissue from damage by the human complement system. It
accelerates decay of the alternative-pathway C3 convertase,
C3bBb, and is a cofactor for factor I-mediated cleavage of
the opsonin C3b. Numerous mutations and single-nucleotide
polymorphisms (SNPs) occur in the gene encoding FH and the
resulting missense mutations and truncation products result in
altered functionality that predisposes to the development of
the serious renal condition atypical haemolytic uraemic
syndrome (aHUS). Other polymorphisms are linked to
membranoproliferative glomerulonephritis and macular
degeneration. The two C-terminal modules of FH (FH19-20)
harbour numerous aHUS-associated mutations that disrupt
the ability of factor H to protect host cells from complement-
mediated damage. In this work, the crystal structure of an
aHUS-associated T1184R variant of FH19-20 at a resolution
of 1.52 A˚ is described. It is shown that this mutation has
negligible structural effects but causes a significant change in
the electrostatic surface of these two domains. Mechanisms
are discussed by which this mutation may alter FH–ligand
interactions, particularly with regard to the extension of a
region of this molecule within module 20 that has been
associated with the binding of glycosaminoglycans (GAGs) or
sialic acid residues.
Received 25 March 2011
Accepted 24 April 2011
PDB Reference: T1184R
variant of complement
regulator factor H, 3r62.
1. Introduction
Complement factor H (FH) plays an essential role in the
regulation of the alternative pathway of complement by
preventing the amplification of the activation-specific C3
fragment, C3b, on self-surfaces. Mutations and SNPs in the FH
gene are linked to diseases of the eye and kidney caused by an
overactive complement system (reviewed in de Co´rboba & de
Jorge, 2008). FH is an abundant 155 kDa soluble glycoprotein
comprising 20 tandemly arranged complement control protein
modules (CCPs). These compact modules each comprise
approximately 60 amino-acid residues and occur widely
amongst the regulators of complement activation (RCA)
family of proteins. FH acts as a cofactor for complement factor
I (FI) that proteolytically cleaves C3b to its inactive form iC3b.
FH also prevents the formation, and accelerates the decay, of
the alternative-pathway convertase complex consisting of C3b
and Bb (C3bBb; Whaley & Ruddy, 1976; Weiler et al., 1976;
Pangburn et al., 1977) that otherwise enzymatically cleaves C3
to generate more C3b (an opsonin) and C3a (an anaphyla-
toxin). FH binds very effectively to C3b and C3bBb, which are
associated with self-surfaces (as opposed to foreign surfaces),
since it recognizes a composite binding site formed by C3b
and specific polyanionic markers such as glycosaminoglycans
and sialic acid (Meri & Pangburn, 1994; Pangburn, 2000).
Crucially, FH does not bind efficiently to, nor protect from
complement, foreign surfaces that lack such markers (Pang-
burn, 2000). FH is therefore integral to the ability of the innate
immune response to discriminate between host cells and
pathogens.
Two regions of FH interact cooperatively with C3b: the
amino-terminal four CCP modules (FH1-4) and the two
carboxyl-terminal CCP modules (FH19-20) (Gordon et al.,
1995; Pangburn, 2002; Schmidt et al., 2008; Sharma & Pang-
burn, 1996). High-resolution crystallographic data have been
obtained for these two primary contact sites in the forms of
FH1-4–C3b and FH19-20–C3d complexes (Wu et al., 2009;
Kajander et al., 2011; Morgan et al., 2011). These two terminal
regions of FH clamp onto C3b, with the intervening 14 CCP
modules of the molecule adopting a loop-like arrangement.
The CCP19-20 site additionally binds via CCP20 to surface
research papers
594 Morgan et al.  T1184R variant of complement regulator factor H Acta Cryst. (2011). D67, 593–600
Figure 1
(a) Crystals of T1184R FH19-20. (b) A representative X-ray diffraction image from a T1184R FH19-20 crystal. The edge of the detector corresponds to a
resolution of 1.27 A˚. (c) A cartoon representation of the asymmetric unit of the FH19-20 T1184R X-ray crystal structure comprising two individual
monomers (PDB entry 3r62). -Strands B and D and the early part of the loop between D and E of CCP19 comprise the majority of the binding
interface between the C-terminus of FH and C3b. (d) An OMIT map highlighting the Thr1184-to-Arg mutation. The resolution of the electron density
(2Fo  Fc map shown in blue) map is 1.52 A˚ and is contoured at 1. The OMIT map shown was calculated by refining Thr1184 in place of Arg. Clear
Fo  Fc density (green) is observed for the arginine side chain.
polyanions, thus contributing crucially to self-tissue recogni-
tion (Morgan et al., 2011; Schmidt et al., 2008; Kajander et al.,
2011). An additional polyanion-binding site occurs on CCP7
(Blackmore et al., 1996, 1998; Pangburn et al., 1991; Herbert et
al., 2007; Morgan et al., 2011).
Haemolytic uraemic syndrome (HUS), which is character-
ized by thrombocytopenia, microangiopathic haemolytic
anaemia and renal failure, is classified as either diarrhoeal-
associated or non-diarrhoeal/atypical HUS (aHUS). The
former, accounting for more than 90% of cases, is commonly a
sequela of Escherichia coliO57:H7 infections, but aHUS is not
infection-related and has a much poorer prognosis. Environ-
mental and genetic risk factors that have been linked to the
pathogenesis of aHUS include numerous mutations in FH as
well as other complement proteins involved in the alternative
pathway (reviewed in Kavanagh et al., 2006; de Co´rdoba &
de Jorge, 2008). The C3b-binding and polyanion-recognition
CCP19-20 region of FH is a hotspot for missense mutations
that predispose to aHUS (Zipfel et al., 1999; Warwicker et al.,
1998; Venables et al., 2006; Richards et al., 2001; Caprioli et al.,
2003) and has been subjected to intense structural and func-
tional analysis. In this study, we report the three-dimensional
structure of an aHUS-associated T1184R form of FH CCP19-
20 (FH19-20) at 1.52 A˚ resolution. We discuss our structure in
the context of functional data for the T1184R mutant, struc-
tural knowledge concerning the FH–C3b and FH–GAG
interactions, and a putative FH–C3d interaction.
2. Materials and methods
2.1. Protein production and crystallization
Recombinant T1184R FH19-20 was produced and purified
as previously described (Ferreira et al., 2009; Herbert et al.,
2006). Briefly, DNA encoding the fragment containing human
FH residues 1107–1231 (native sequence numbering) was
cloned into the Pichia pastoris expression vector pPICZ. A
QuikChange site-directed mutagenesis kit (Stratagene) was
employed to generate a threonine-to-arginine substitution at
position 1184 according to the manufacturer’s instructions.
This T1184R mutation has been associated with the devel-
opment of aHUS (Kavanagh et al., 2006). Plasmid DNA
containing the T1184R-modified FH19-20 insert was subse-
quently used to transform a P. pastoris expression host. The
resulting recombinant T1184R FH19-20 was secreted into the
medium and then purified by cation-exchange chromato-
graphy. The purified recombinant T1184R FH19-20 protein
contains an additional four-residue cloning artefact (EAEF)
at the N-terminus. Successful introduction of the single-site
mutation was confirmed by mass spectroscopy (not shown).
Crystals of T1184R FH19-20 were grown at 290 K by the
vapour-diffusion method from hanging drops. The drops
consisted of equal volumes of protein solution concentrated to
6.6 mg ml1 in phosphate-buffered saline pH 7.4 (containing
137 mM NaCl, 8.1 mM Na2HPO4, 2.7 mM KCl, 1.5 mM
KH2PO4), 5 mM EDTA and 0.005%(w/v) sodium azide and
well solution consisting of 0.1M Tris–HCl pH 8.5 and 12%
polyethylene glycol 8000 as the precipitant. Crystals grew after
approximately two weeks (Fig. 1a). Crystals were flash-frozen
in liquid nitrogen after successive soaks in cryoprotectant
solutions containing 10 and 25%(v/v) glycerol.
2.2. Data collection and structure determination
Diffraction data were measured on beamline I03 of the
Diamond Light Source using an ADSC Q315 CCD detector
(Fig. 1b) and a crystal-to-detector distance of 219 mm. A total
of 60 images were collected over 180 with an exposure time of
0.25 s at 50% attenuation. Data were indexed with MOSFLM
and merged and scaled with SCALA. The structure of the
T1184R variant of FH19-20 was solved by molecular
replacement using the program Phaser (McCoy et al., 2007),
with the previously determined NMR structure (PDB entry
2bzm; Herbert et al., 2006) as a search model. There was a
clear molecular-replacement solution with two monomers in
the crystallographic asymmetric unit. The initial model was
subjected to ten cycles of restrained refinement using the
program REFMAC (Murshudov et al., 2011), resulting in R
and Rfree values of 31.85 and 35.06, respectively. Using the
program Coot (Emsley & Cowtan, 2004), Thr1184 was
mutated to Arg1184, for which clear Fo  Fc electron density
was observed, alternative side-chain conformers were
constructed and the additional residues were added to the N-
terminus. The model was then subjected to several rounds of
restrained refinement, resulting in R and Rfree values of 26.75
and 30.34, respectively. Water molecules were added to the
model using Coot. Water molecules were accepted based on
the following criteria: no less than a 3.2 peak height in the
difference maps, hydrogen-bonding distances to protein atoms
of between 2.0 and 3.5 A˚ and a B factor of less than 55 A˚2.
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Table 1
Data-collection and refinement statistics.
Values in parentheses are for the highest resolution shell.
Data collection
Space group P212121
Unit-cell parameters (A˚) a = 36.89, b = 52.84, c = 142.63
Resolution (A˚) 1.52
Rmerge (%) 10.9 (68.1)
Rmeas (%) 11.8 (76.9)
hI/(I)i 11.5 (2.1)
Completeness (%) 99.6 (95.6)
Multiplicity 6.5 (4.6)
Wilson B factor (A˚2) 24.23
Average mosaicity () 0.60
Refinement
Resolution (A˚) 42.46–1.52
No. of reflections 41260
Rwork/Rfree 17.78/20.80
No. of atoms
Protein 2175
Ligand (glycerol) 6
Water 398
Average protein B factors (A˚2)
Protein 16.80
Ligand 32.12
Water 30.47
R.m.s. deviations
Bond lengths (A˚) 0.03
Bond angles () 2.37
Areas of disorder were carefully modelled into Fo  Fc elec-
tron density and the changes in the R and Rfree values were
used to assess the final model quality. This resulted in a final
model of 248 residues, composed of two T1184R FH19-20
molecules (molecule 1/chain A = Gly1107–Arg1231, molecule
2/chain B = Glu1105–Arg1231), and 398 water molecules. The
R and Rfree values converged after 20 cycles of REFMAC at
17.78 and 20.80, respectively. Data-reduction and refinement
statistics are summarized in Table 1.
2.3. Validation and deposition
The geometry of the model was assessed using MolProbity
(Chen et al., 2010) and quaternary-structure analysis was
performed using the PISA server (Krissinel & Henrick, 2007).
Atomic coordinates and the experimental structure factors for
the 1.52 A˚ structure of the T1184R FH19-20 variant have been
deposited in the Protein Data Bank with code 3r62.
3. Results and discussion
The structure of the T1184R aHUS-associated variant of
FH19-20 was successfully determined at a resolution of 1.52 A˚
(Figs. 1c and 1d). The crystal structure was solved by mole-
cular replacement using the NMR structure of wild-type
FH19-20 as the search model (PDB entry 2bzm; Herbert et al.,
2006). The orthorhombic crystal form contained two protein
molecules in the asymmetric unit, with a solvent content of
47%. The overall architecture is similar
to that previously reported for wild-type
FH19-20 (Jokiranta et al., 2006; Herbert
et al., 2006) and to those of two other
single-site mutants of FH19-20 for
which structures have been determined
by crystallography: Q1139A, which is
located within module 19, determined at
1.65 A˚ and R1203S, which is located
within module 20, determined at 2.0 A˚
(Bhattacharjee et al., 2010). With the
exception of the NMR solution
structure (Herbert et al., 2006), all of
these FH19-20 molecules have been
crystallized as tetrameric assemblies
(wild-type FH19-20, PDB entry 2g7i,
Jokiranta et al., 2006; Q1139A, PDB
entry 3kzv, Bhattacharjee et al., 2010;
R1203A, PDB entry 3kzj, Bhattacharjee
et al., 2010) and indeed, a potential
physiological role for oligomerization
has been suggested previously (Jokir-
anta et al., 2006). In comparison, in our
study two near-identical molecules of
T1184R FH19-20 are observed in the
asymmetric unit, forming a dimer that is
stabilized by contacts between residues
within CCP19 of the respective FH
molecules. In particular, residues
Asp1116, Glu1159, Asp1162, Cys1163,
His1165 and Asp1220 from chain A, and
Ser1122, Ser1133, Glu1135, Lys1148,
Arg1149, Thr1151 and Arg1153 from
chain B are involved in the formation of
intermolecular hydrogen bonds and salt
bridges. Analysis and scoring of this
dimer interface using the program PISA
(Krissinel & Henrick, 2007) indicates
that FH19-20 dimerization is likely to be
the result of crystal packing. Accord-
ingly, the dimer interface observed in
this structural elucidation is not likely to
be physiologically relevant to the regu-
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Figure 2
(a) A superimposition of the T1184R FH19-20 (yellow) structure with wild-type FH19-20 (green)
belonging to the C3d–wild-type FH19-20 complex (determined at 2.1 A˚ resolution; PDB entry 3oxu;
Morgan et al., 2011). Amino acids belonging to two interacting helices 7 (orange; residues 170–189)
and 4 (cyan; residues 103–119) of C3d-1 (which is shown in grey) form the majority of the
interactions with FH (which extrapolates to the C3b–FH19-20 interface), predominantly interacting
with module 19. An additional C3d molecule (C3d-2) binds to a putative secondary site (as
proposed by Kajander et al., 2011) located on module 20 of FH. The heterotrimer shown was
generated using the wild-type C3d–FH19-20 complex (Morgan et al., 2011). (b, c) Two enlarged
views of the secondary C3d–FH19-20 interface. The T1184R mutation is unlikely to directly affect
C3b binding at the primary site as it occurs towards the C-terminal region of module 20, but it is
close to a putative secondary C3d-binding site. Potential hydrogen bonds (shown as dashed red
lines) between Arg1184 and the carbonyl O atom of Ile100 and Val97 are shown.
lation of complement on self-surfaces. These data are in
accordance with previously reported analytical ultra-
centrifugation studies, which demonstrate that full-length FH
(CCP1-20) is monomeric under solution conditions (Aslam &
Perkins, 2001).
In a previous study reporting the link between the missense
T1184R mutation and the development of aHUS, levels of
circulating FH were reported to be normal in a sporadic
patient (Richards et al., 2001). Accordingly, any differences in
host-cell recognition by FH or regulation of complement by
FH should be attributed to structural or functional perturba-
tions resulting from the threonine-to-arginine substitution
rather than to altered levels of expression. In our structure of
the T1184R variant of FH19-20 each monomer adopts a rod-
like structure in which the two CCP modules are aligned in
an end-to-end manner. Thus, the crystal structure reveals that
neither the intermodular orientation nor the global fold of
CCP20 are perturbed by this mutation. Indeed, the structures
of the wild-type and T1184R forms of FH19-20 may be
superimposed (backbone atoms) with an r.m.s.d. of 1.03 A˚
(T1184R, PDB entry 3r62, chainA; FH19-20, PDB entry 3oxu,
chain F, Morgan et al., 2011) (Fig. 2). Structural changes are
thus highly localized to the immediate vicinity of the mutated
side chain. On the other hand, the gain of a positive charge in
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Figure 3
(a) A superposition of T1184R FH19-20 (yellow) with wild-type FH19-20 (green) belonging to the C3d–wild-type FH19-20 heterotrimer (PDB entry
3oxu; Morgan et al., 2011) and D1119G/Q1139A FH19-20 belonging to the C3d–D1119G/Q1139A FH19-20 heterotrimer (determined at 2.3 A˚
resolution; PDB entry 2xqw; Kajander et al., 2011; shown in faded blue). The C3d–wild-type FH19-20 heterotrimer is coloured identically to that shown
in Fig. 2. C3d-2 belonging to the C3d–D1119G/Q1139A FH19-20 complex, although making similar interactions with FH (Figs. 2b and 2c), is swivelled
12.8 A˚ (measured between the carbonyl O atom of Glu47) towards C3d-1 (as indicated by the arrow). (b) Arg1184 belonging to T1184R FH19-20
sterically clashes with C3d-2 (specifically residues Asn98–Ile102) when superposed onto the structure of D1119G/Q1139A FH19-20 (belonging to the
C3d–D1119G/Q1139A FH19-20 heterotrimer). (c) A superposition of T1184R FH19-20 (yellow) with wild-type FH19-20 (green) belonging to the C3d–
wild-type FH19-20 heterotrimer. (d) Electrostatic surface representation of C3d-2 (calculated using the APBS plug-in for PyMOL) highlighting the
highly negatively (red) charged concave surface and the interacting Arg1203 (forming a salt bridge with Glu160 of C3d-2). A model of the positively
charged Arg1184 (belonging to T1184R FH19-20) interacting with a region of negative charge on the surface of C3d-2 (details of the interaction are
shown in Fig. 2).
the mutant has more widespread effects on the electrostatic
properties of CCP20, as discussed below in the context of the
critical C3b/self-surface recognition properties of FH.
The structure of wild-type FH19-20 in complex with C3d
has recently been determined by X-ray crystallography
(Morgan et al., 2011), as was the structure of a functionally
deficient double mutant D1119G/Q1139A of FH19-20 in
complex with C3d (Kajander et al., 2011). Both structure
determinations identified virtually identical binding sites on
C3d that can be extrapolated to the context of the physio-
logical C3b–FH interaction (Figs. 2 and 3). Both studies
demonstrated that C3b engagement by FH19-20 primarily
involves residues from within CCP19, with additional contri-
butions from residues within the cleft between the modules
and the N-terminal region of CCP20 (Figs. 2 and 3; Kajander et
al., 2011; Morgan et al., 2011). This proposed C3b-binding site
on FH19-20 is supported by NMR and by binding studies with
mutant proteins, many of which are linked to aHUS. Several
aHUS-associated C3b missense mutations have also been
identified within, or in close proximity to, this interface
(Fre´meaux-Bacchi et al., 2008; Miller et al., 2010). Engineered
C3d mutants designed to interrogate this interface also result
in reduced binding to FH19-20 (Kajander et al., 2011; Morgan
et al., 2011). The current structure indicates very clearly that
the T1184R mutation would have no direct effect on this
binding site.
In addition to this CCP19-dominated C3b-binding surface, a
distinct interaction was observed in each of the reported C3d–
FH19-20 complexes between CCP20 of FH and an additional
C3d molecule; the orientation of this second C3d molecule
relative to CCP20 varies between the two complexes (Fig. 3).
Kajander and coworkers proposed on the basis of their
structure that the formation of a physiological C3b–FH–C3d
trimolecular complex may occur on the cell surface (Fig. 2).
However, it is unclear how commonly such a complex would
occur in a physiological setting since it would require a very
specific juxtaposition of a C3b molecule (bound mainly to
module 19) and an adjacent C3d molecule (bound to module
20 of the same FH molecule). Moreover, while NMR data
supported the aforementioned CCP19-dominated binding site,
they were not consistent with this additional CCP20-mediated
interaction.
There have been three conflicting studies of the binding
of T1184R FH19-20 to one or more of C3b, C3dg and C3d
(Ferreira et al., 2009; Lehtinen et al., 2009; Morgan et al., 2011).
Ferreira and coworkers and Morgan and coworkers reported
that a T1184R mutant exhibited increased binding relative to
wild-type to C3b, with less significant increases or null changes
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Figure 4
Electrostatic surface representations of (a) wild-type FH19-20 (PDB
entry 2g7i; Jokiranta et al., 2006) and (b) T1184R FH19-20 (PDB entry
3r62). Further indicated on both molecules as a blue mesh is a positive
isosurface map contoured at +4 kT/e. The location of residue 1184,
corresponding to a threonine in wild-type FH and an arginine in this
aHUS-associated variant, is indicated in orange. Positively and negatively
charged areas of these molecules are indicated in blue and red,
respectively. This figure was generated using the APBS plugin for
PyMOL (DeLano Scientific LLC). The PDB2PQR server was utilized to
generate the PQR file used to run APBS (Dolinsky et al., 2004).
Table 2
Reported binding affinities of wild-type FH19-20 and T1184R FH19-20 for C3b, C3dg, C3d and heparin.
Wild-type FH19-20 T1184R FH19-20 Reference
C3b 6 mM (C3b; CM5) 2 mM (C3b; CM5) Ferreira et al. (2009)†
9.1  0.4 mM (C3b–biotin; SA) 5 mM (C3b–biotin; SA) Ferreira et al. (2009)†
Decrease relative to wild type Lehtinen et al. (2009)‡
C3dg 3.8  0.5 mM (CM5) 4.4  0.2 mM (CM5) Morgan et al. (2011)†
C3d 6.2  0.4 mM (recombinant C3d; CM5) 4.2  0.1 mM (recombinant C3d; CM5) Morgan et al. (2011)†
8.2  0.6 mM (plasma C3d; CM5) 6.8  0.2 mM (plasma C3d; CM5) Morgan et al. (2011)†
No change relative to wild type Lehtinen et al. (2009)‡
Heparin 100% (377 mM NaCl) 129% (488 mM NaCl) Ferreira et al. (2009)§
Increase relative to wild type Lehtinen et al. (2009)§
† Kd values for FH19-20–C3 (C3b, C3dg or C3d) fragments coupled to CM5 or streptavidin (SA) sensor chips were recorded by surface plasmon resonance under physiological ionic
strength buffer conditions (Ferreira et al., 2009; Morgan et al., 2011). ‡ Binding affinities were calculated by the relative capacity of unlabelled wild-type or T1184R forms of FH19-20 to
inhibit binding of 125I-labelled FH19-20 to C3b or C3d under half physiological ionic strength buffer conditions (Lehtinen et al., 2009). § Relative heparin-binding affinities of wild-type
and T1184R forms of FH19-20 were recorded as a measure of the elution profile (peak maxima values given) of these recombinant proteins from heparin-conjugated beads in the
presence of a linear NaCl gradient (Ferreira et al., 2009; Lehtinen et al., 2009).
observed for C3d and C3dg, respectively (Ferreira et al., 2009;
Morgan et al., 2011; Table 2). In contrast, Lehtinen and
coworkers reported that T1184R exhibited a decreased
capacity to inhibit binding of radiolabelled wild-type FH19-20
to immobilized C3b (although no such decrease was observed
for immobilized C3d; Table 2; Lehtinen et al., 2009). The
substitution of an arginine for a threonine has a profound
effect on the electrostatics within this region and accordingly
may have electrostatic steering effects (Fig. 4) that could
explain any of the aforementioned binding results. Interest-
ingly, however, when our new T1184R FH19-20 structure is
modelled onto the crystal complex of C3d–FH19-20, Arg1184
appears to directly overlap with the additional putative
CCP20–C3d interface (Kajander et al., 2011; Figs. 2 and 3).
Thus, the lack of any substantive effect of this mutation on
C3d-binding (upon which all studies agree) is not consistent
with the CCP20–C3d interaction observed in the crystal
structure being physiologically important.
Numerous aHUS-associated missense mutations within
module 20 modify the GAG-binding properties of FH19-20
(Fig. 5). Generally speaking, removing positive charge from
CCP20 reduces affinity for heparin (a GAG mimetic) and for
models of host-cell surfaces (Ferreira et al., 2009; Lehtinen
et al., 2009). Specifically, positive-charge-deficient CCP20
mutants exhibit decreased binding to heparin-conjugated
media (Ferreira et al., 2009; Lehtinen et al., 2009) and to
activated mouse glomerular endothelial cells (mGEnC-1;
Lehtinen et al., 2009). They also have reduced capacity to
inhibit binding of radiolabelled FH19-20 to C3b-coated sheep
erythrocytes (Ferreira et al., 2009). Conversely, the addition of
positive charge increases affinity for heparin and mGEnC-1
cells (Ferreira et al., 2009; Lehtinen et al., 2009). For example,
T1184R FH19-20 binds more strongly to a heparin-conjugated
matrix than wild-type FH19-20 (Ferreira et al., 2009; Lehtinen
et al., 2009; Table 2). In related experiments, NMR has been
used to identify residues whose resonances undergo significant
perturbations upon titration of the fully sulfated heparin
tetrasaccharide or the octasaccharide fraction of heparin into
samples of FH19-20 or the FH19-20–C3d complex, respec-
tively (Herbert et al., 2006; Morgan et al., 2011; Fig. 5). The
new structure shows that T1184R extends an electropositive
region of CCP20 that has previously been implicated by NMR
in GAG binding (Figs. 4 and 5). This is then consistent with a
model in which T1184R enhances binding between module 20
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Figure 5
Primary sequence of wild-type FH19-20 with aHUS-associated missense and deletion mutations indicated (Saunders et al., 2007). Shown in yellow are
those residues which have been identified by X-ray crystallography as contributing to a C3b–FH19-20 interface (Kajander et al., 2011; Morgan et al.,
2011). Indicated in red are those residues which have been identified by NMR line-broadening studies as being important in C3d (C3b) binding (Morgan
et al., 2011). Indicated in orange are residues which have been proposed to form an additional physiological C3d-binding surface (Kajander et al., 2011).
Indicated in blue are residues which have been identified by NMR chemical shift perturbation studies as being involved in heparin (GAG-mimetic)
binding (Herbert et al., 2006; Morgan et al., 2011). (b) The C3d–wild-type FH19-20 heterotrimer, highlighting the positions of aHUS-associated missense
and deletion mutations (shown as spheres).
and cell-surface GAGs, thereby disturbing the fine balance of
interactions needed to ensure that an FH molecule functions
effectively when confronted with multiple C3b molecules
tethered to a self-surface.
In conclusion, the disease-associated T1184R mutation
perturbs neither the structure of FH nor its primary C3b-
interaction site. The location of this mutation would overlap
with a putative CCP20–C3d interaction observed in crystal
structures, but in fact has no effect on C3d binding. It is likely
to contribute to the development of aHUS by significantly
altering the GAG-binding properties of the C-terminal
module of FH, although perturbation of an additional putative
C3d-binding site cannot be ruled out on the basis of these
data.
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